Mutations in IGF Pathway Genes Associated With Prostate Cancer Mortality

Get Permission

In a study reported in the Journal of the National Cancer Institute, Cao and colleagues identified mutations in insulin-like growth factor (IGF) pathway genes that were significantly associated with mortality in prostate cancer.

Analysis of 530 single nucleotide polymorphisms (SNPs) in 26 IGF pathway-related genes in 5,887 European-ancestry prostate cancer patients, including 704 who died from the disease, showed that mutations in the IGF signaling pathway overall were significantly associated with prostate cancer mortality (P = .03), with mutation in IGF2-AS and SSTR2 being the main contributors to the association (both P = .04).

In SNP-specific analysis, 36 SNPs were associated with prostate cancer mortality (P < .05 for trend). However, only three SNPs in IGF2-AS remained significant after gene-based corrections; two were in linkage disequilibrium (rs1004446 and rs3741211) and one (rs4366464) was independent.

The hazard ratios per each additional risk allele were 1.19 (P = .003 for trend) for rs3741211 and 1.44 (P < .001 for trend) for rs4366464, with the effect of rs4366464 remaining significant after correction for all SNPs (P = .04 for trend). In 2,424 patients, including 313 who died, prediagnostic circulating IGF1 and IGFBP3 levels were not significantly associated with mortality.

The investigators concluded, “The IGF signaling pathway, primarily IGF2-AS and SSTR2 genes, may be important in [prostate cancer] survival.” ■

Cao Y, et al: J Natl Cancer Inst 106:dju085, 2014




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.